Race and subset analyses in clinical trials: Time to get serious about data integration

Journal of the National Cancer Institute

Volumn 103, Issue 20, 2011, Pages 1486-1488

  Polite, Blase N ^a   Sylvester, Brooke E ^a   Olopade, Olufunmilayo I ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; PANITUMUMAB; PROTEIN BCL 2;

CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; DATA ANALYSIS; EDITORIAL; ETHNICITY; GENETIC ASSOCIATION; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE INTERVAL; RECURRENCE FREE SURVIVAL;

AFRICAN AMERICANS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; FEMALE; HUMANS; MALE;

EID: 80054925903     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr382     Document Type: Editorial

References (33)

1. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116(3):544-573.
2. Soneji S, Iyer SS, Armstrong K, et al. Racial disparities in stage-specific colorectal cancer mortality: 1960-2005. Am J Public Health. 2010;100(10):1912-1916.
3. Surveillance, Epidemiology, and End Results (SEER) Program. SEER Stat Database: Incidence-SEER 9 Regs Research Data, Nov 2010 Sub (1973-2008).
4. Linked To County Attributes-Total U.S., 1969-2009 Counties. National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. www.seer.cancer.gov. Released April 2011, based on the November 2010 submission Accessed August 5, 2011.
5. American Cancer Society. Cancer Facts & Figures for African Americans 2009-2010. Atlanta, GA: American Cancer Society; 2009.
6. Baldwin LM, Dobie SA, Billingsley K, et al. Explaining black-white differences in receipt of recommended colon cancer treatment. J Natl Cancer Inst. 2005;97(16):1211-1220. (Pubitemid 41258227)
7. Polite BN, Dignam JJ, Olopade OI. Colorectal cancer model of health disparities: understanding mortality differences in minority populations. J Clin Oncol. 2006;24(14):2179-2187. (Pubitemid 46630690)
8. Hines RB, Shanmugam C, Waterbor JW, et al. Effect of comorbidity and body mass index on the survival of African-American and Caucasian patients with colon cancer. Cancer. 2009;115(24):5798-5806.
9. Yothers G, Sargent DJ, Wolmark N, et al. Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. J Natl Cancer Inst. 2011;103(20):1498-1506.
10. Dignam JJ, Colangelo L, Tian W, et al. Outcomes among African-Americans and Caucasians in colon cancer adjuvant therapy trials: findings from the National Surgical Adjuvant Breast and Bowel Project. J Natl Cancer Inst. 1999;91(22):1933-1940.
11. Fearon E, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759-767.
12. Kinzler K, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996;87(2):159-170. (Pubitemid 26358996)
13. Markowitz S, Bertagnolli M. Molecular basis of colorectal cancer. New Engl J Med. 2009;361(25):2449-2460.
14. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010;28(3):466-474.
15. Sargent D, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of effficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28(20):3219-3226.
16. Walther A, Johnstone E, Swanton C, et al. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer. 2009;9(7):489-499.
17. Le Marchand L, Wilkens L, Kolonel L, et al. The MTHFR C677T polymorphism and colorectal cancer: the Multiethnic Cohort Study. Cancer Epidemiol Biomarkers Prev. 2005;14(5):1198-1203. (Pubitemid 40656467)
18. Polite BN, Sing A, Sargent DJ, et al. Exploring racial differences in outcome and treatment for metastatic colorectal cancer: results from a large prospective observational cohort study (BRiTE) [published online ahead of print July 28, 2011]. Cancer. 2011; doi:10.1002/cncr.26394.
19. Sanoff HK, Sargent DJ, Green EM, et al. Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. J Clin Oncol. 2009;27(25):4109-4115.
20. McCollum AD, Catalano PJ, Haller DG, et al. Outcomes and toxicity in African-American and Caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. J Natl Cancer Inst. 2002;94(15):1160-1167. (Pubitemid 34919053)
21. Tammemagi CM, Nerenz D, Neslund-Dudas C, et al. Comorbidity and survival disparities among black and white patients with breast cancer. JAMA. 2005;294(14):1765-1772. (Pubitemid 41434622)
22. Hofmann LJ, Lee S, Waddell B, et al. Effect of race on colon cancer treatment and outcomes in the Department of Defense healthcare system. Dis Colon Rectum. 2010;53(1):9-15.
23. Obeidat NA, Pradel FG, Zuckerman IH, et al. Racial/ethnic and age disparities in chemotherapy selection for colorectal cancer. Am J Manag Care. 2010;16(7):515-522.
24. Sinicrope FA, Foster NR, Thibodeau SN, et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst. 2011;103(11):863-875.
25. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-2342. (Pubitemid 38702844)
26. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408-1417.
27. Van Cutsem E, Kohne CH, Lang I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29(15):2011-2019.
28. Ribic C, Sargent D, Moore M, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. New Engl J Med. 2003;349(3):247-257. (Pubitemid 36859476)
29. Ahnen D, Feigl P, Quan G. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group Study. Cancer Res. 1998;58(6):1149-1158. (Pubitemid 28183202)
30. Liang J, Huang K, Cheng Y, et al. P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection. Int J Cancer. 2002;97(4):451-457. (Pubitemid 34027803)
31. Zhu H, Guo W, Zhang L, et al. Bcl-XL small interfering RNA suppresses the proliferation of 5-fluorouracil-resistant human colon cancer cells. Mol Cancer Ther. 2005;4(3):451-456. (Pubitemid 40443930)
32. Schulze-Bergkamen H, Ehrenberg R, Hickmann L, et al. Bcl-Xl and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells. World J Gastroenterol. 2008;14(24):3829-3840.
33. Watanabe T, Wu T, Catalano P, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. New Engl J Med. 2001;344(16):1196-1206. (Pubitemid 32319494)